Human Cardiovascular Physiology Laboratory, Department of Health and Exercise Science, Vascular Physiology Research Group, Department of Biomedical Sciences, Colorado State University, Fort Collins 80523-1582, USA.
Am J Physiol Heart Circ Physiol. 2011 Oct;301(4):H1302-10. doi: 10.1152/ajpheart.00469.2011. Epub 2011 Jul 22.
ATP is an endothelium-dependent vasodilator, and findings regarding the underlying signaling mechanisms are equivocal. We sought to determine the independent and interactive roles of nitric oxide (NO) and vasodilating prostaglandins (PGs) in ATP-mediated vasodilation in young, healthy humans and determine whether any potential role was dependent on ATP dose or the timing of inhibition. In protocol 1 (n = 18), a dose-response curve to intrabrachial infusion of ATP was performed before and after both single and combined inhibition of NO synthase [N(G)-monomethyl-L-arginine (L-NMMA)] and cyclooxygenase (ketorolac). Forearm blood flow (FBF) was measured via venous occlusion plethysmography and forearm vascular conductance (FVC) was calculated. In this protocol, neither individual nor combined NO/PG inhibition had any effect on the vasodilatory response (P = 0.22-0.99). In protocol 2 (n = 16), we determined whether any possible contribution of both NO and PGs to ATP vasodilation was greater at low vs. high doses of ATP and whether inhibition during steady-state infusion of the respective dose of ATP impacted the dilation. FBF in this protocol was measured via Doppler ultrasound. In protocol 2, infusion of low (n = 8)- and high-dose (n = 8) ATP for 5 min evoked a significant increase in FVC above baseline (low = 198 ± 24%; high = 706 ± 79%). Infusion of L-NMMA and ketorolac together reduced steady-state FVC during both low- and high-dose ATP (P < 0.05), and in a subsequent trial with continuous NO/PG blockade, the vasodilator response from baseline to 5 min of steady-state infusion was similarly reduced for both low (ΔFVC = -31 ± 11%)- and high-dose ATP (ΔFVC -25 ± 11%; P = 0.70 low vs. high dose). Collectively, our findings indicate a potential modest role for NO and PGs in the vasodilatory response to exogenous ATP in the human forearm that does not appear to be dose or timing dependent; however, this is dependent on the method for assessing forearm vascular responses. Importantly, the majority of ATP-mediated vasodilation is independent of these putative endothelium-dependent pathways in humans.
三磷酸腺苷(ATP)是一种内皮依赖性血管扩张剂,但其潜在信号机制的研究结果尚存在争议。本研究旨在探讨一氧化氮(NO)和血管扩张性前列腺素(PGs)在年轻健康人体中对 ATP 介导的血管舒张的独立和交互作用,并确定任何潜在作用是否依赖于 ATP 剂量或抑制时间。在方案 1(n=18)中,在单次和联合抑制一氧化氮合酶(N(G)-单甲基-L-精氨酸(L-NMMA))和环氧化酶(酮咯酸)前后,通过肱动脉内输注 ATP 进行剂量反应曲线。通过静脉闭塞容积描记法测量前臂血流(FBF),并计算前臂血管传导性(FVC)。在该方案中,单独或联合的 NO/PG 抑制对血管舒张反应均无影响(P=0.22-0.99)。在方案 2(n=16)中,我们确定在低剂量与高剂量的 ATP 时,NO 和 PG 对 ATP 血管舒张的贡献是否更大,以及在各自剂量的 ATP 稳态输注期间的抑制是否会影响扩张。该方案中通过多普勒超声测量 FBF。在方案 2 中,5 分钟输注低剂量(n=8)和高剂量(n=8)ATP 可使 FVC 显著高于基础值(低剂量:198±24%;高剂量:706±79%)。联合输注 L-NMMA 和酮咯酸可降低低剂量和高剂量 ATP 期间的稳态 FVC(P<0.05),在随后的连续 NO/PG 阻断试验中,低剂量和高剂量 ATP 从基线到 5 分钟稳态输注的血管舒张反应均显著降低(ΔFVC=-31±11%;ΔFVC=-25±11%;P=0.70,低剂量 vs. 高剂量)。总之,我们的研究结果表明,NO 和 PGs 在人体前臂对外源性 ATP 的血管舒张反应中可能具有一定作用,但这种作用似乎不依赖于剂量或时间;然而,这取决于评估前臂血管反应的方法。重要的是,在人类中,大多数 ATP 介导的血管舒张独立于这些假定的内皮依赖性途径。